The outcomes of randomized prospective trials have shown that SGLT2 inhibition reduces the likelihood of major adverse cardiovascular events and also reduces mortality, the rate of hospitalization for heart failure, and the progression of DKD [118,119]. Here, SLC5A2 is linked to heart failure.